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INTRODUCTION 
Post operative nausea vomiting (PONV) is an alarming surgical complication
1
 
with critical clinical consequences leading to delayed recovery in patients 
undergoing general anaesthesia. PONV continues to rank as most undesirable 
surgical outcome despite of multiple advances in recent years with use of non-
pharmacological and pharmacological strategies to reduce its incidence to 
certain extent. Since the inception of general anaesthesia, PONV remains an 
important complication after surgery for which no complete solution is available 
till date. PONV had gained more attention in 1991 after Kapur has described 
this issue as big “little problem” 2. It is distressing for patient as well as for the 
treating physician as it affects post-operative care and recovery substantially. 
PONV is   an unpleasant sensation which patient often describes it as worse 
than post-operative pain.  
Causes of PONV are multi factorial which are primarily categorised into patient 
related factors, pre- surgical factors and post-surgical factors. Due to various 
factors contributing to development of PONV quantification of risk of PONV in 
individual patient is difficult. Apfel and colleagues
3 
mentioned major predictors 
of PONV that include age, obesity
4
, female patient,
5,6
 past history of PONV or 
motion sickness
7
 , use of opioids
8 
as an adjunct to anaesthesia and non smoker 
group
9
. Other pre-surgical and intra-surgical factors that contribute to PONV are 
pre-operative anxiety, underlying medical condition, hydration status, use of 
volatile anaesthetics, type and duration of surgery and type of   anaesthesia
3, 6, 10
. 
In general population, incidence of PONV is very high (i.e.30-40%) and which 
increases further in high risk individuals up to 80%
7
. In addition to such 
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displeasing sensation PONV may have adverse consequences like pulmonary 
aspiration, Hypovolemia, electrolyte imbalance and wound dehiscence which 
prolongs post operative as well as total hospital stay and increase hospital cost
11
. 
The Prevention of above said complications improve quality of life and reduce 
unexpected hospital admissions and duration of hospital stay leading to overall 
decrease in financial burden to the patient. 
Patho-physiological mechanism of PONV is complex due to involvement of 
different neurotransmitters at different sites. Activation of vomiting centre 
mainly occurs due to stimulation of chemoreceptor trigger zone (CTZ) situated 
at the floor of fourth ventricle. CTZ constitutes receptor for dopamine, 
serotonin, opioids, acetylcholine and neurotransmitter substance P. Each of 
these receptors innervates the pathway that stimulate vomiting centre. At least 
three nerves and seven neurotransmitters play role in causation of PONV. There 
are several classes of drugs that constitute basic of anti-emetic therapy. Several 
pharmacological agents
1
 like anti-histaminics, butyrophenones, dopamine 
receptor antagonist and dexamethasone has been tried for the prevention of 
PONV but none of them found to be superior. Despite extensive research and 
introduction of new classes of anti-emetic agents with better safety and efficacy 
profile, there seems to be little progress in reducing incidence of PONV. As 
single agent has not been proved to be complete solution to tackle this problem; 
recent research has advanced the use of  
combination anti-emetic therapy acting at more than one molecular site to 
control PONV. Use of more than two anti-emetic drugs has its own 
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disadvantages in the form of added side effects and drug interactions. Therefore 
development of single molecule with prolonged action and lesser side effects is 
encouraged. 
Ondansetron, a 5HT3 receptor antagonist is used as antiemetic in patients of 
malignancy along with chemotherapy 
11 
and also approved in prevention of 
PONV. Palonosetron is considered to be second generation latest 5 HT3 receptor 
antagonist with unique action and much longer half life than other 5HT3 
antagonists offering flexibility to use as once a day. It has higher receptor 
affinity compared to other 5HT3 antagonists and requires much smaller dose 
(0.075mg I.V)
 12
 than ondansetron for the prophylaxis of PONV.  
Safety and efficacy of Palonosetron in comparison to ondansetron has been well 
established in recent studies in patients undergoing specific surgeries like 
laparoscopic cholecystectomy, gynaecological laparoscopic surgery, paediatric 
surgery and lower segment caesarean section but most of the studies are 
restricted to laparoscopic or gynaecological or thyroid surgeries. Very minimal 
data is available on efficacy of palonosetron in all different types of surgeries 
under individual research. Hence Palonosetron study was undertaken to 
compare its safety and efficacy with ondansetron in all adult patients planned 
for surgical procedures under general anaesthesia.   
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AIMS AND OBJECTIVES 
 
 Primary objectives: 
 To assess the efficacy of IV Palonosetron in preventing post operative 
nausea vomiting (PONV) in comparison with IV ondansetron 
 To assess safety of IV Palonosetron compared to IV ondansetron in 
relation to adverse effects in post surgical patients undergoing GA 
 
 
Secondary objective: 
 To find whether both drugs are comparable with demographic parameters 
like age, sex, height and weight   
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REVIEW OF LITERATURE 
PONV definition:  PONV is the second most common complaint after post-
operative pain. One of the first extensive descriptions of phenomenon of nausea 
and vomiting was by John Snow, published in 1848 with one and half years of 
chloroform discovery as anaesthetic agent in Britain. The term PONV became 
more popular in 1992 after landmark review by Watcha and White
1
. The word 
“vomiting” is developed from Latin word “vomitorium”13 meaning fast exit. 
The word “nausea”14 derived from a Greek word “nautia” is source for word 
nausea which means seasickness. It is described as discomfort in the stomach 
with the need to vomit. The retching means reverse movements of contents of 
oesophagus as well as stomach without vomiting. By definition PONV is 
nausea, retching or vomiting observed during first 24-48 hours of surgery.  A 
well designed study conducted in United States
15
 and Europe
16
 showed that 
patients are willing to pay from their pocket for efficacious anti-emetic agent to 
get rid of unpleasant experience which could be worse than post-operative pain.   
Epidemiology: Though PONV is one of the leading complications after 
anaesthesia and is a most important factor in determining the length of hospital 
stay, its exact incidence has not been quantified
17, 18
. Incidence of PONV is 
variable and it ranges from 30-40% which further increases up to 80%
7
 in high 
risk patients. Higher incidence of PONV is seen in patient with use of opoid 
analgesics, laparoscopic surgery, breast surgery and strabismus surgery. 
Greatest incidence is observed in young non-smoking women
19
. High incidence 
of PONV can be reduced by propofol anaesthesia. 
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In view of need to improve treatment strategies in PONV almost 3000 
randomized controlled studies have been published in numerous journals and 
300 new studies are being published every year
14
. This recent information can 
be very much handy and useful for Clinicians and Anaesthetists in managing 
PONV more effectively in their day to day practice.  
Aetiology: Pathways for Nausea and Vomiting 
Nausea and vomiting may be induced by various pathways involving complex 
interaction between area postrema (CTZ), vomiting centre (nucleus of tractus 
solitarius), cortex, thalamus, hypothalamus, vestibular apparatus and two cranial 
nerves namely VIII
th
 and X
th
 nerve. 
Various receptors that have been found in the vomiting centre are responsible 
for act of emesis are: Muscarinic (M1), Histamine (H1), serotonin (5HT3) and 
neurokinin 1 (NK1) receptors.  Vomiting centre receives four afferent inputs
20
 
from following area: 
 
1. CTZ: is located at the base of fourth ventricle and constitutes D2, opioid, 
5HT3 and NK1 receptors. 
2.  Vestibular apparatus: is rich in M1 and H1 receptors and plays important 
role in motion sickness through VIII
th
 cranial nerve. 
 
3. GIT: irritation of GI mucosa by chemotherapy, radiotherapy, gastric 
distension, and acute gastroenteritis leads to release of serotonin and 
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activation of 5HT3 receptors carries afferent information through vagal 
nerve to vomiting centre and CTZ. 
4. CNS: Afferent from cortex, hypothalamus, and thalamus are carried to 
the CTZ after stimulation of these organs by sense of smell, severe pain, 
sight of vomiting and emotional factors. 
Neurologic pathway responsible for genesis of emesis is shown in 
following diagram
21
.  
 
Risk Factors: 
The term risk factor was first mentioned by Framingham study in relation to 
heart disease. Certain factors like high blood pressure, dyslipidemia and  
smoking
22 
were assessed to find likely causal relation for development of heart 
disease. Information of risk factors is valuable for development of risk 
assessment tools which can predict risk of particular disease. In PONV, females 
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have more risk than males as they are more susceptible to certain stimuli
23, 24 
like motion, opoids, chemotherapy and anaesthetic agents given through 
inhalational route.  
Risk of PONV in females is thrice
25
 more than males. If both genders are equal 
then incidence of PONV for female to male would be 45% and 15%. Major 
surgical procedures in female population increases incidence up to 50-60% 
while in small gynaecological procedures incidence could be as low as 7% 
26
. A 
female with non smoking status and received opioids will have further increase 
in risk hence it is more useful to consider PONV as a multi-factorial in origin. 
Risk factors can be classified into three independent predictors which have been 
elaborated below. 
I. Patient related independent predictors:  
1. Female gender: risk of PONV is high in females compared to males 
irrespective of anaesthetic technique used. Exact cause is not known but 
probably may be due to lower threshold to motion sickness
27
 and emotional 
tolerability than males. It is highly specific predictor of PONV with odds 
ratio of 2.6
28
. 
2. Non smoking status: individuals always develop nausea to their first 
cigarette due to nicotinic effects on body. One can expect higher incidence 
of PONV in smokers than non smokers. Interestingly findings from few    
Studies are contradictory. Cohen and associates mentioned 1.8 times
25
 more 
risk to non smokers than smokers. This study was further strengthened by 
large meta-analysis study
28
. 
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3. History of PONV, nausea or migraine: there will be variable response to 
emetogenic stimuli and patient may not recollect previous history correctly. 
Hence PONV history predictor is having only 50% sensitivity
29
. 
4. Age: incidence of PONV reduces with increase in age. Eberhart and 
associates have conducted study in children and concluded that at the age of 
3 years or after PONV incidence is increased
30
. 
5. Anxiety: anxiety may affect PONV but study results are conflicting. A small 
cohort study in children
31
 is not supportive and large randomized control 
trial in adults
32
 also showed weak association. Anxiety may not be useful 
parameter for predicting PONV. 
II) Anaesthesia related independent predictors: 
1. Use of opioids: Opioid use before surgery showed no difference in PONV 
when compared with meperidine but showed more frequency of PONV in 
comparison to barbiturates
33
. During intra-operative stage, different type of 
opioid showed different results. One article mentioned that alfentanil was 
associated with less PONV compared with sufentanil or fentanyl 
34
. While 
another study stated that no significant difference was observed in 
remifentanil and fentanyl comparative study. Cann C and colleagues
35
 
concluded that morphine-6-glucoronide is found effective than morphine in 
reducing PONV but in another comparative study conducted by Hanna  
M H and associates
36
 showed no  statistically significant difference. Use of 
opioids post-operatively increase the risk twice
3 
but rather than type of 
opioid, dose
37
plays more important role in increased incidence of PONV. 
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Non-opioids reduce PONV incidence and thereby decreasing use of opioids 
by 30-50%
38
. 
2. Propofol and inhaled anaesthetic agents:  Propofol has anti-emetic property 
and may reduce incidence of PONV. Scuderi and colleagues
39
 conducted 
trial where small dose propofol was given as IV infusion in females 
planned for laparoscopy. Author could not be able to prove anti-emetic 
effect of propofol. In another randomized trial
40
, healthy individuals were 
received propofol, midazolam or placebo and then apomorphine was given 
by infusion. There was increase in threshold for nausea in sedative dose but 
not for non-sedative dose. With these inconsistent results, concrete 
conclusion on anti-emetic effect of propofol cannot be drawn. As compared 
to regional anaesthesia, general anaesthesia brings higher risk of PONV 
which indirectly indicate contribution of inhalational anaesthetics for 
higher incidence
26 
of PONV. A study conducted with sevoflurane
41
 showed 
increased incidence of PONV up to 80% that clearly supports emetogenic 
property of inhalational agents. A meta-analysis study conducted by 
Gupta
42
 and associates demonstrated no difference in PONV among 
volatile agents like isoflurane, sevoflurane and desflurane. Similar types of 
conclusions were observed by Macario
43
 and colleagues study as well as 
Wallenborn
44
  
and co-worker study. Emetogenic effect of nitrous oxide has been 
demonstrated in various studies
45, 46
 but effect may not be as strong as 
volatile anaesthetics
47
. More than emetogenic potential, nitrous oxide trials 
showed serious complications like hypoxia, wound infections and fever.  
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3. Duration of anaesthesia: Incidence of PONV is associated with duration of 
anaesthesia
26, 44, 47 
but varies widely in extent. In addition to this, other 
factors like use of inhaled anaesthetics
26
, opoids further aggravate 
magnitude of PONV. In general longer duration surgical procedures are 
associated with more incidence of PONV. 
III) Surgery related independent predictors: 
Various types of surgical intervention may be associated with high incidence of 
PONV. Laparoscopic procedures, ENT surgeries (Tympanoplasty, adeno-
tonsillectomy and vestibular stimulation), gynaecological procedures and breast 
surgeries
48-50 
have an increased risk of PONV up to 50%. But many times other 
underlying patient related or anaesthesia related factors contribute to higher 
incidence of PONV. Hence risk assessment should be done on underlying 
independent predictors. Several studies describe the fact that type of surgery is 
not independent factor for development of PONV
51-54
. However some article 
identified that different type of surgical procedures are independent predictors 
of         PONV
26,29,32
. Strabismus surgery is not predictive factor in adult but 
well documented in PONV in children.  
 
Risk Assessment: 
As PONV is multifactorial, patient’s risk can be better judged by logistic 
regression analysis. Palazzo and Evans
55
 were the first to apply multiple logistic 
regressions while Koivuranta and co-workers
56
 were the first to publish 
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predictive models on the basis of above mentioned study. By using strong 
predictors
56
 like female sex, history of motion sickness, past history of PONV, 
operative time more than one hour and non-smokers, simplified models were 
developed. Factor positivity from 1 to 5 showed risk of PONV from 18%, 42%, 
54%,74% and 87% 
 
respectively
56
. However for point zero, predictor risk of 
PONV was 17%. Of many PONV logistic models; Afpel’s PONV score is used 
frequently for its simplicity. 
Simplified risk score
3
 predicting PONV for adults: 
 
Absolute risk difference: is effectiveness of anti-emetic drug with specific risk 
profile. Suppose, PONV incidence in high risk group is 80% and use of 5HT3 
antagonist reduced incidence up to 60% then relative risk difference is 20%. So 
if 5HT3 antagonists are given in all 100 high risk individuals, 20% of them will 
have reduced risk. In short 1 out of 5 will be benefited with 5HT3 antagonists. In 
other words to prevent PONV in one patient, 5 patients should be treated 
prophylactically. 
Hence number needed to treat (NNT) =1/ARD 
Relative risk reduction ratio is calculated as one minus relative risk reduction. 
 
Risk Factors  Points 
Female gender 1 
Non-smoker 1 
History of PONV 1 
Post-operative opioids 1 
Risk score 0...4 
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Measurement of PONV: 
As nausea, vomiting and retching can occur separately or in combination, 
assessment should be done independently. Hence various scales are used for 
assessment of PONV are inadequate. VAS
14, 19
 (Visual Analogue Scale) is most 
commonly used for measurement of PONV in which there is 10cm horizontal 
line with left side corresponds to no nausea and right side to imaginable nausea. 
 
 
 
Another ways of assessment of nausea is by numeric rating scale
14
 where patient 
rates his nausea from 0 to 10 with 0 corresponds to no nausea and 10 for worst 
possible nausea.  
 
 
 
Another easy approach for assessing Nausea is verbal rating scale where 
patients describe their symptoms as no nausea, mild, moderate or severe nausea 
and scores are given as [0],[1-3],[4-6] and [7-10] respectively. As intensity of 
nausea varies from time to time, repeated scoring is required for assessment of 
PONV. Hence it is better to take average of the score.  
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Several types of scales to rate severity of nausea are shown below: 
Visual Analogue Scale for nausea  
 
(www.rch.org.au) 
Baxter Retching Faces Nausea Scale 
(www.rch.org.au) 
Prophylactic anti-emetic Policies:  
PONV treatment is mainly classified into  
1) Non-pharmacological strategies  
2) Contemporary strategies  
3) Pharmacological Strategies 
1. Non-pharmacological strategies: 
Few non-pharmacological techniques like acupressure
57
and 
acupuncture
57, 58 
have been tried in prevention of PONV but did not gain 
much popularity. 
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2. Contemporary strategies: 
i) Peri-operative pain management: is most important strategy in 
anaesthetic practice to reduce complications of anaesthesia. Also right 
choice of analgesic agent is necessary to control post operative pain. 
Frequent use of opioids during intra and post operative period can 
increase the risk of PONV. Under such situation it is wise to use non 
opioid analgesics for post operative pain relief.
38
 A systematic review by 
Marrett et al 
38
 demonstrated significant reduction in PONV with use of 
Non opioids. 
ii) Use of regional or local anaesthesia: Use of general anaesthetic agents 
can lead to increased risk of PONV hence with use of regional or local 
anaesthesia can be good alternative in patients undergoing general 
anaesthesia provided surgery can be attainable by using regional or local 
anaesthesia. However risk of developing nausea and vomiting after spinal 
anaesthesia is not less but pathophysiology is slightly different. Few 
independent predictors responsible for post-spinal PONV are female sex, 
intra-operative tachycardia, use of opioids and hypotension
59, 60
. 
 3 . Pharmacological Strategies: 
(1) Dopamine Antagonists: Metoclopramide has been used since olden days to 
prevent PONV due to its anti-emetic as well as established pro-kinetic 
properties
61 
but major issue with metoclopramide is development of extra-
pyramidal symptoms seen in almost 10% of individuals. Although it can be 
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treated with anti-histaminics and benzodiazepines 
62
 dopamine antagonists are 
not frequently used for treatment of PONV. 
Droperidol is another drug of choice for PONV with potent anti-emetic property 
and similar efficacy with smaller dose
63 
(0.625 to 1.25 mg) than 
metoclopramide. Even though many studies have investigated its 
pharmacokinetic properties, its minimal effective dose and ideal time of 
administration has not been established well. Also it is contraindicated in 
patients with prolonged QT interval. Haloperidol has advantage over droperidol 
due to its relative safety and is considered being as effective as ondansetron
64
. 
Other drugs like alizapride, prochlorperazine and few neuroleptic agents are 
rarely used. 
Domperidone is an antique drug similar to metoclopramide used in vomiting 
caused by cytotoxic agent and for gastrointestinal symptoms like nausea, 
retching. As it does not cross blood brain barrier, central side effects are less 
observed
13
. 
(2)  Histamine Antagonists: As these drugs have been proved their successful 
use in motion sickness and with additional anti-cholinergic activity, 
Diphenhydramine, dimenhydinate, cyclizine and promethazine are used in 
prevention of PONV in selected individuals. Their use is limited by frequent 
side effects like urinary retention, blurring of vision and extra-pyramidal 
syndrome
14, 65
. 
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(3) Anti-cholinergics: Of many anti-cholinergic agents scopolamine is well 
established agent in treatment of motion sickness and specialized delivery of 
scopolamine through trans-dermal route appears to be effective in treatment of 
PONV
66
 when patch is applied a night prior to surgery or early morning on the 
day of surgery. As trans-dermal scopolamine causes pupillary dilation, its use in 
neurological surgeries is restricted where evaluation of pupillary reaction is vital 
in post operative management. 
(4) Neurokinin Antagonists: Substance P binds to NK1 receptor and induce 
emetogenic pathway. Some studies have proved efficacy of NK1 antagonists 
against PONV. Diemunsch and co workers
67
 demonstrated efficacy of NK1 
antagonist GR205171 in a pilot study conducted in patients undergoing 
gynaecological surgeries. Gan et al
68
 conducted randomized controlled trial 
with NK1 antagonists using dose of 40mg and 120 mg  and ondansetron with 
dose of 4 mg.  In this triple arm study author remarked that aprepitant; a NK1 
antagonist is superior to ondansetron in controlling PONV in first 24 and 48 
hrs. Another newer NK1 antagonist casopitant is in pipeline to prove its 
superiority over ondansetron
69
. Synthetic cannabinol (nobilone) also have 
been proved to be effective where vomiting is primarily due to CTZ 
stimulation
13
. 
(5) Corticosteroids like Dexamethasone: Dexamethasone has been used in 
animal experiment and proved to produce antiemetic effect through inhibition of 
nucleus of tractus solitarii rather than area postrema
70
. Carlisle and colleagues
71
 
has opined that dexamethasone is having similar efficacy to ondansetron. As 
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dexamethasone is having slow onset of action, it is not common practice to use 
dexamethasone alone in PONV. 
(6)  Benzodiazepines: although lorazepam and alprazolam are not anti-emetic 
agents but due to sedative, anxiolytic and amnesic effect they help in reducing 
anticipatory component of nausea and vomiting in patients
21
. 
(7)  Serotonin antagonists: 5 HT3 antagonists principally used for treatment of 
chemotherapy induced nausea vomiting (CINV) as well as treatment of 
PONV.
13
 The primary site of action of these drugs is on CTZ. They are 
precisely used in vomiting than nausea that encounter after surgery. Due to 
additional safety profile compared to other anti-emetic agents they have gained 
more popularity in managing PONV. Commonly used 5HT3 antagonists are: 
ondansetron, palonosetron, granisetron and dolasetron. The most widely 
prescribed 5HT3 antagonist is ondansetron which is a prototype drug. The main 
difference among these agents are related to chemical structures, receptor 
affinity and pharmacokinetic profile.
21
   
All 5HT3 antagonists act as competitive antagonist by binding to extracellular 
binding site except palonosetron which display allosteric binding. This 
distinguishable binding makes palonosetron unique in anti-emetic property with 
strong receptor affinity. 
Anti-emetic agents are also classified depending upon their potency
72
.  
 Most Potent: Palonosetron, ondansetron, granisetron and metoclopramide 
 Moderately Potent: Phenothiazines, droperidol and cannabinoids 
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 Weak Anti-emetic agent: Anti-cholinergics, anti-histaminics and 
benzodiazepines. 
 Adjunctive agents: Dexamethasone 
Until recently ondansetron was the drug of choice for treatment of PONV and 
CINV, but various comparative studies had been in the favour of palonosetron 
in term of safety and efficacy. Even though ondansetron is less expensive, cost 
benefit ratio
73 
proved superiority of palonosetron over ondansetron. 
Pharmacology of Palonosetron: 
Chemical structure: 
Palonosetron hydrochloride exists as single isomer and posses following 
structural formula
74
. 
 
Chemically , palonosetron hydrochloride is (3aS)-2-(3S)-1-
Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinoline-1-
one monohydro-chloride. The molecular formula for palonosetron is 
C19H24N2OHCl and molecular weight is 332.87. 
31 | P a g e  
 
Mechanism of action: 
Palonosetron acts by binding to 5HT3 receptor as an antagonist
13
. 5HT3 receptor 
is a pentamer with a centrally permeable cylindrical body. Various genes for 
5HT3 subtype had been identified. 5HT3A and 5 HT3B receptor subunits
75 
are 
expressed in area postrema, nucleus tractus solitarii and entero-chromaffin cells 
of GIT. All 5 HT receptors are G-Protein Coupled Receptors and 5 HT3 
receptors are inotropic ligand gated ion channels. 
Activation of pre-synaptic 5HT3 receptor leads to rapid rise in Ca
2+
 inside the 
cell which produces biological response through series of events. In addition, 
5HT3 receptor also modulates release of various neurotransmitters like 
serotonin, dopamine, neurokinin, cholecystokinin and acetylcholine which are 
capable of inducing PONV after their activation.  
Pharmacokinetics of Palonosetron: 
There is not much significant difference in pharmacokinetics of palonosetron in 
comparison to other 5 HT3 antagonists. After intravenous administration, it 
achieves adequate plasma concentration and 62% binds to plasma proteins
75
. It 
has volume of distribution of 8.3±2.5 L/kg and is metabolised in liver by 
oxidation and hydroxylation producing two primary inactive compounds: N-
oxide palonosetron and 6-S-hydroxy palonosetron. Almost 40% of drug is 
excreted unchanged in urine. Palonosetron exhibit high receptor binding 
property (Pki=10.45) and prolonged elimination half life about 40 hours
74
. 
Dose and route of administration
12, 73
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Each 1.5 ml vial of palonosetron contains 0.075mg of palonosetron 
hydrochloride. It is preferably given as intravenous route 10-30 minutes before 
induction of anaesthesia. 
Safety of palonosetron: 
The safety of all 5 HT3 antagonists is very well proved in various 
randomized
76
studies. Common side effects are constipation, headache, rashes 
and prolongation of QT interval leading to arrhythmias. Palonosetron showed 
less incidence of QT prolongation even with increasing dose. Transient increase 
in hepatic enzyme has been mentioned but occurs less frequently.  
Drug interactions:  
As palonosetron is neither enzyme inducer nor enzyme inhibitor, its drug 
interaction potential appears to be low
73
. However adverse reaction with 
apomorphine demonstrated profound hypotension and unconsciousness. 
Use in specific population: 
Pregnancy: Teratogenicity has been confirmed in animal studies but not well 
controlled studies observed in pregnant women. It is contraindicated in 
pregnancy with category B evidence
73
. As palonosetron is excreted through 
milk, serious adverse reaction in infants can occur hence it is not advised in 
nursing mothers
14
. Also its safety below 18 years has not been established.  
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Studies in accordance with our study: 
Many studies assessed comparison of palonosetron versus ondansetron or other 
5HT3 antagonists and have revealed superiority of palonosetron in term of 
safety and efficacy. 
Kovac and colleagues
77 
demonstrated safety and efficacy of various doses of 
palonosetron in female patients undergoing elective gynaecological or breast 
surgery. A multicentric trial was conducted among 544 patients. After random 
allocation, patients were divided into three groups. Primary efficacy end point 
was assessed by number of complete responders (CR) in all three groups who 
received either of three different doses of palonosetron (0.025mg, 0.050 mg and 
0.075mg).  The study concluded that single dose of 0.075 mg of palonosetron 
was effective in preventing PONV and not lower doses. 
 
Loha and associates
78 
conducted a single blinded parallel group study where 98 
patients were allocated to either palonosetron group or ondansetron group. The 
surgical technique, type of anaesthesia and anaesthetic regimen was unique. The 
primary effectiveness was measured by frequency of nausea vomiting and 
number of CR and secondary safety end points were assessed by observing any 
adverse drug reactions. The study concluded that palonosetron was comparable 
to ondansetron for prophylaxis of PONV in laparoscopic cholecystectomy when 
intravenous palonosetron  given as single dose just before induction.  
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Moon and co-authors
79 
have evaluated efficacy of palonosetron versus 
ondansetron in a hundred non smoking females who were allocated randomly to 
either group. One group received 8 mg of ondansetron as a bolus followed by 
16mg combined with patient controlled analgesia (PCA) regimen. Another 
group received intravenous 0.075mg palonosetron. Patients were treated with 
opioid analgesics like fentanyl to alleviate post operative pain. Incidence of 
PONV, adverse effects, severity of nausea and effect of rescue medication use 
were measured at 0-2 and 2-24 hrs. In a final conclusion, author remarked that 
palonosetron was more effective than ondansetron in high risk group where post 
operative opioids were used to control pain.  
Bajwa et al
80 
conducted a comparative clinical study in 60 patients undergoing 
day care surgery were randomly assigned in groups received 8mg of 
ondansetron or 0.075 mg of palonosetron just before induction of anaesthesia. 
All patients were observed for first 6 hours for PONV episodes and number of 
time rescue medication used. Patients were followed up on phone and statistical 
analysis was done. In palonosetron group 6.66% and 3.33% had nausea and 
vomiting respectively while in ondansetron group it was 20% and 13.33% 
respectively which was statistically significant. Author opined that palonosetron 
is better drug in comparison with ondansetron in controlling PONV in day care 
surgeries. 
Bhattacharjee and co-workers
81 
demonstrated the efficacy of palonosetron 
against granisetron in 60 female patients who had undergone laparoscopic 
cholecystectomy. Patients were randomly assigned to group P or group G and  
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received 75 µgm of palonosetron and 2.5 mg of granisetron respectively. 
Incidence of complete response (CR) and adverse effects were assessed 
statistically. From statistical observations author remarked that palonosetron 
was more effective as a prophylactic anti-emetic agent when compared with 
granisetron. However no statistical difference between two groups had been 
observed in relation to incidence of side effects. 
Chun and associates
82 
concluded the superiority of palonosetron in reducing 
PONV during first 72 hrs of post operative period among 204 patients. Two 
groups were assigned after randomization where one group received placebo 
(normal saline) and other group received 0.075mg palonosetron. Nausea 
severity, PONV incidence and rescue medication were the main parameters to 
assess efficacy. A conclusive remark by author mentioned that palonosetron 
helps in reducing incidence of PONV during post operative period. 
Sadaba et al
83 
opined about bioavailability of I.V. palonosetron in comparison 
with sc route and found equal bioavailability through both the routes. In their 
study appropriate patients were selected where platinum based chemotherapy 
was induced from October 2009 to July 2010. Patients were randomized to 
receive palonosetron either intravenous or subcutaneous route and primary end 
point for assessment was bioavailability. In a cross over designed study 
patient’s blood samples were collected at required intervals and statistical 
analysis was performed by ANOVA. Author revealed that there was no 
statistical difference in AUC. 
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Candiotti and colleagues
84 
organised open label study to compare better choice 
of rescue anti-emetics between first generation and second generation 5HT3 
antagonists in reducing PONV. In this multicenter trial outpatients planned for 
abdominal or gynaecological surgery by laparoscopic method were selected and 
received ondansetron 4 mg intravenously just before anaesthesia. By 
randomization, patients were allotted to receive rescue treatment either with 
palonosetron 0.075mg or ondansetron 4 mg through intravenous route. Out of 
enrolled 220 patients 98 patients received rescue medication (48 palonosetron 
and 50 ondansetron). Complete control assessed at 72 hours of drug treatment 
found no statistical significance in both groups (25% in palonosetron group 
against 18% in ondansetron group). Even though not much significant 
difference was observed in two active arms, author did not forget to mention 
about down going trend in palonosetron group towards decrease in episodes of 
vomiting. Author further suggested that larger studies are necessary to prove 
superiority of palonosetron as a rescue anti-emetic agent.  
Sharma and co-workers
85 
compared efficacy of palonosetron with ondansetron 
in a prospective study where 90 patients undergoing hysterectomy by 
laparoscopic approach were selected. Patients were randomized into group I 
who received intravenous 0.075mg palonosetron with 8 mg of dexamethasone. 
In group II, 4 mg of ondansetron with same dose of dexamethasone were 
injected. In group I, during first 2 hrs no one had nausea, three had vomiting and 
4% required rescue medication. While in group II, 8 had nausea (P=0.013) and 
vomiting and 20% needed rescue antiemetic therapy. After 24 hrs, neither 
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 group had either nausea or vomiting. From above observations author derived 
conclusion that combination therapy with dexamethasone and palonosetron was 
more beneficial in treating early as well as late cases of PONV.  
Mansour
86 
has conducted study in high risk individuals with ASA (American 
Society of Anaesthesiologists) grade I or II. After randomization and blinding of 
patient as well as investigator, study was conducted in one hundred and fifty 
patients. Three equal groups were assigned for study in which one group 
received Dexamethasone and normal saline, second group received 
dexamethasone and metoclopramide and third group received dexamethasone 
and palonosetron. Author concluded that combination of palonosetron and 
dexamethasone was safe in early as well as late phase of PONV
1
. 
Kim et al
87 
conducted a comparative study between palonosetron and 
ondansetron in non smoking females scheduled for gynaecologic surgery by 
laparoscopic manner. About 100 patients of ASA grade I or II were randomized 
into palonosetron group and ondansetron group. In ondansetron group, 8 mg of 
ondansetron was given intravenously followed by continuous infusion of 16 mg 
which was added in patient controlled analgesia regimen. Intravenous 0.075 mg 
of palonosetron was administered just before induction of anaesthesia in 
palonosetron group and normal saline was added in patient controlled analgesia 
regimen. PONV episodes were recorded at 2, 24, 48 and 72 hrs of post operative 
period. Overall incidence of PONV was 52% in ondansetron group and 48% in 
palonosetron group in 0-72 hr after surgery.  
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Author inferred from observations that no benefit of one drug over the other in 
preventing PONV.  
Morrow et al
88 
demonstrated superiority of palonosetron over other first 
generation 5HT3 antagonists. In this analytic study, different types of cancer 
patients who were about to receive emetogenic chemotherapy from four 
different trials were selected. Eligible patients from four study groups were 
grouped into two where first arm received single dose of 0.25mg or 0.75mg of 
IV palonosetron. In second arm either 32 mg of ondansetron,100 mg of 
dolasetron or 40 µgm/kg  of granisetron was given half an hour before induction 
of chemotherapy. In a large study population of 2913 malignancy patients, 
complete control for palonosetron was 66% and 46% in acute and late phase 
while in ondansetron arm it was 63% and 43% respectively. Author drawn 
concluding remark mentioning that palonosetron received group were free of 
nausea on every day and very few had severe nausea. In addition, requirement 
of rescue medication was also less in palonosetron group. 
Mattiuzzi et al
89
 compared two doses of palonosetron with ondansetron in 
patients of AML undergoing chemotherapy. Forty seven patients enrolled in one 
group received ondansetron 8 mg stat and then 24 mg continuous infusion. 
Another two groups having 48 patients in each arm received either palonosetron 
0.25 mg daily for 5 days or same dose of palonosetron on alternate day (Day1,3, 
and 5). In each group 77% were without nausea on first day and percentage of 
nausea from second to fifth day was reduced in all groups. On day 6and 7, 
patients from group who received palonosetron daily were free from nausea. 
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(p=0.01) Author remarked that daily palonosetron was superior to ondansetron 
in prophylaxis of late CINV. 
 
Moon et al
90 
derived conclusion from a study where 93 patients were planned to 
undergo gynaecologic laparoscopic procedures. Patients were randomized into 
two groups to receive 0.075 mg of IV palonosetron or 40 mg oral aprepitant. In 
a double blinded study complete response was assessed 1-48 hours of surgery. 
At 0 and 2 hrs, severity of nausea was significantly less (p<0.05) in aprepitant 
group. Although consumption of fentanyl was less in aprepitant group, large 
amount of rescue analgesics required to control pain in this group. In final 
comment author stated that palonosetron and aprepitant both are effective in 
PONV prophylaxis and further suggested that combined use of these drugs 
would provide more benefit compared to single use alone. 
In a randomized study done by  Bicer et al
 91
 where about 150 children under 2 
to 12 years of age group undergoing strabismus surgery were assigned to 
receive palonosetron with dose of  0.5,1.0,1.5 µgm/kg. All patients were 
assessed at four different intervals (0-2 hrs, 2-6 hrs, 6-24 hrs and 24-48n hrs) for 
episodes of nausea, vomiting or retching. Nausea severity was assessed by 
numerical scale. Percentage of PONV in children received 0.5 or 1 µgm/kg of 
palonosetron was 24% while PONV incidence was 4% less in children receiving 
1.5µgm/kg of palonosetron. Author mentioned efficacy of different doses of 
palonosetron in controlling PONV and stressed upon further evaluation for 
these dosages. 
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Bergese et al
92
 demonstrated efficacy of triple regimen anti-emetic therapy with 
palonosetron, dexamethasone and promethazine in patients undergoing 
craniotomy and also mentioned about less risk of QT prolongation on ECG in 
palonosetron combined anti-emetic regimen. Forty participants were given triple 
dose regimen containing 0.075 mg palonosetron, 10 mg dexamethasone and 25 
mg promethazine. Patients were assessed post-operatively every 24 hours for 5 
days for PONV symptoms. Incidence of PONV after 24 hrs of surgery was 30% 
(nausea incidence was 30% and emesis incidence was 7.5%). Overall incidence 
of PONV was 30% and complete response was seen in 70% in whom no nausea 
or vomiting has been observed from day1 to day5. As per Author’s opinion, in 
combination anti-emetic regimen palonosetron is effective in preventing PONV 
without additional cardiac risk of side effects. (No QT prolongation) 
Kim and associates
93
 conducted prospective study in 109 non smoking females 
posted for planned laparoscopic surgery. After randomization by using 
computerized random number tables patient were assigned into three groups. 
All three   groups received either ondansetron 4mg or palonosetron 0.075 mg or 
ramosetron 0.3mg. Primary efficacy parameters were assessed by using 
variables like number of PONV episodes, severity of nausea and number of 
times rescue medication used. Overall PONV incidence was found low in 
palonosetron based group (22.2%, 11.1%, 5.6%) in comparison to other two 
active treatment groups. (Ondansetron 77%, 48.6%, 28.6% and ramosetron 
60.5%, 28.9%, 18.4%) Need of rescue anti-emetic was reduced in palonosetron 
arm (P<0.001). By Kaplan Meier analysis method palonosetron ranked first 
antiemetic followed by ramosetron and ondansetron. 
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Chattopadhyay and collegues
94
 have inferred in a study where 109 women 
participated in a randomized study. Patients were allocated into two groups 
where first group received palonosetron (0.075mg) and second group received 
ramosetron (0.3mg) immediately after the birth of the baby. Participants were 
blinded to the procedures and investigator was also unaware about the fact that 
which therapeutic regimen was received to either group. Complete response in 
first 2 hrs of medication was 85% in palonosetron group and 83.3% in 
ramosetron group. After 2-24 hrs of medication, incidence of CR in 
palonosetron group was 70.9% and 53.7% in ramosetron group which was 
statistically significant. (p<0.05) After extrapolation of data, author remarked 
that palonosetron is better prophylactic agent than ramosetron in prevention of 
delayed PONV. 
Lorusso et al
95
 demonstrated that single dose combination therapy of 
palonosetron and dexamethasone is effective in controlling CINV in patients 
receiving multi day based chemotherapy (MD-CT). This prospective 
uncontrolled trial was planned in oncology OPD of Vito Fazzi Hospital in Italy. 
Patients were given 0.25 mg of palonosetron along with 20 mg of 
dexamethasone half an hour prior to induction of chemotherapy. All patients 
were asked to keep record in diary from day 1 to day 7. Complete response, 
complete control (complete response but mild nausea) and food intake amount 
per week were assessed.  Out of enrolled 50 patients, 80% showed CR and 78% 
showed CC. From first to last chemotherapy cycles CR was observed in 76 to 
88% and CC was seen in 62 to 88%of individuals.  Patients with CR showed 
more food intake per week than non complete responders and the difference was 
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statistically significant. (p<0.0001) Final concluding remark from author 
mentioned that palonosetron with single dose was capable of preventing CINV 
in all scheduled chemotherapy cycles. 
Morganroth and associates
96 
have assessed safety of single dose of 
palonosetron towards cardiovascular related side effect (QT prolongation) in 
phase I trial. It was double dummy and parallel arm study in healthy participants 
where moxifloxacin was given as positive control. After initial evaluation 
participants were allocated into five groups. First group received placebo in oral 
as well as IV form, second group received 0.25 mg of IV palonosetron with oral 
placebo, third group received 0.75 mg of IV palonosetron (three fold higher than 
previous group) with oral placebo, fourth group received 2.25 mg of IV 
palonosetron (three fold higher than previous group) with oral placebo and last 
group received IV placebo with 400 mg of oral moxifloxacin. The study showed 
no prolongation of QT interval with confidence interval (CI) of 10 ms. Author 
concluded that palonosetron did not show any adverse effect on cardiovascular 
system even with increase in dose. On the other hand 5HT3
 
antagonists like 
ondansetron and dolasetron reported prolonged QT interval in increasing dose. 
Charbit and collegues
97 
assessed safety of ondansetron, droperidol in a small 
prospective study on a 16 healthy volunteers. After dividing into two equal sex  
groups, participants received either ondansetron or droperidol in first group and 
combination of ondansetron and droperidol or placebo in second group. The 
QTc interval was assessed in all groups. As compared placebo group, 
ondansetron as well as droperidol showed prolonged QTc.  
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Prolonged QTc interval was also observed in a group who received combination 
therapy with ondansetron and droperidol. Author concluded that ondansetron or 
droperidol or their combination had higher risk of cardiovascular adverse effect 
in term of QTc prolongation. 
 
To demonstrate anti-emetic efficacy it is better to conduct study in high risk 
group as these groups will be more benefitted from the intervention than normal 
individuals. Many studies have been conducted to evaluate safety and efficacy 
of anti-emetics in a specific groups undergoing particular type of surgery. We 
cannot make generalization because these findings in one group of population 
who underwent particular type of surgery may not be applicable to other type of 
surgery. There are insufficient data available on participant of all age groups 
and all post operative surgeries under general anaesthesia. To bridge this gap we 
conducted study to assess safety and efficacy of palonosetron against 
ondansetron on population covering all eligible post operative candidates 
undergoing general anaesthesia irrespective their type of surgery.  
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4. MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
The study was initiated after getting approval from the Institutional Ethical 
committee. Approval letter dated 21.01.2015. 
 
Study Design: double blinded randomized controlled study. 
 
Study period: January2015 to February 2016. 
 
Source of Data: All eligible patients of ASA grade I category undergoing 
surgical intervention under general anaesthesia in Karpaga Vinayaga Institute of 
Medical Sciences were enrolled.  
 
Sample Size: sample size was calculated with 5% (p<0.05) level of significance 
and a power of study at 80%. (β error 20%). Sample size required for our study 
was 50 in each group but 8 more samples in each group were added to improve 
accuracy of study results. 
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Inclusion Criteria: 
1. Patients of  either sex between age group 15-60 yrs with ASA grade I 
status  
2. Patient willing to give written informed consent 
Exclusion Criteria: 
1. Pregnancy 
2. Patients with diagnosed case of Acid Peptic Disease 
3. Patient with history of nausea and vomiting pre-operatively 
4. Patient taking anti-emetics or steroids 
5. Patient having major organ involvement like liver, kidney, heart, brain 
and lungs 
6. Chronic alcoholic  
7. Patient with known hypersensitivity to any of the study trial drug 
8. Patient participated in other study trial 
9. Patient with history of motion sickness 
10.  Patients of Malignancy 
Subject enrollment:  
A written informed consent was obtained from all participants in each group 
prior to surgery. Meticulous care was taken in obtaining demographic data, 
details of previous illness and retrieving details like past history of motion 
sickness or PONV. 
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CONSORT diagram of patient distribution: 
 
 
 
 
 
 
 
 
 
 
 
Methodology: 
 
116 out of 129 patients were recruited for the study based upon inclusion and 
exclusion criteria and routine investigations like Hb %, TLC, FBSL, PPBSL, 
BUL, S. Creatinine, Chest X-ray and ECG were recorded.  
 
 
Enrollment 
Participants assessed for study (n=129) 
Excluded from study 
Not fulfilling inclusion 
and exclusion criteria 
(n=13) 
Block randomization (n=116) 
Allocated to Group A 
(Palonosetron) N=58 
 
Allocated to Group B  
Ondansetron    N=58 
 
                Allocation to groups  
No dropout 
 
No dropout 
No dropout 
 
                   Follow-up  
Analysed N=58 
 
Analysed    N=58 
 
                  Statistical analysis   
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Patients were randomly assigned into two equal groups.  
Group A: received palonosetron 0.075 mg intravenously. 
Group B: received ondansetron 8 mg intravenously. 
Block randomization method was used for assigning equal groups. Four letter 
blocks were prepared as: AABB, ABAB, ABBA, BAAB, BABA, BBAA and 
patients were allocated accordingly. For example, if randomly selected block 
would be BAAB then first patient would go to group B, second and third patient 
would go to group A and fourth patient would go to group B. In this way there 
was equal distribution of subjects in each group. 
Before induction of anaesthesia vitals like pulse, respiratory rate, systolic and 
diastolic blood pressure, temperature and oxygen saturation (SPO2) were 
recorded. A covered envelope was provided to anaesthetist where name of drug 
group was mentioned. (Obtained from block randomization) Accordingly either 
palonosetron or ondansetron was administered 10 minutes before anaesthesia. 
After premedication with fentanyl 2µg/kg
14
 and glycopyrrolate
14 
5µg/kg, 
patients were induced with IV propofol 2mg/kg and intubated with succinyl 
choline
14 
and muscle relaxation was achieved by vecuronium bromide 
0.08mg/kg. Patients were reversed back from general anaesthesia with 
neostigmine 0.05mg/kg and glycopyrolate 0.2 mg. All vital parameters like 
pulse, BP, RR, Temperature, SPO2 and ECG were monitored intra operatively 
and post operatively at 0, 6,12,24,48 hrs.  
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Patients were questioned by trained staff or on duty CRRI by using validated 
questionnaire for assessment of safety and efficacy. Efficacy was evaluated by 
complete response,
80,98 
(no episode of nausea or vomiting and no use of rescue 
medication) severity of nausea,
80, 98
  use of rescue medication, and overall 
satisfaction score by 5 point Likert scale within 48 hrs of surgery
98
. Nausea 
severity was measured by Verbal Rating Scale and patients were graded into: no 
nausea 0, mild nausea 1-3, moderate nausea 4-6 and severe nausea 7-10. Those 
who had developed severe nausea or vomiting, rescue antiemetic IV 
metoclopramide (10mg) was administered.  
 
Safety was evaluated for presence of rash, itching or hypotension or any serious 
adverse event during and after surgery. Cardiovascular safety was assessed by 
comparing pre and post-operative ECG by assessing QTc interval. 
 
Statistical analysis: 
Mean, standard deviations and proportions were calculated among the 
groups. Data was entered into excel spread sheet and analysed by using SPSS 
software. Statistical analysis was done by Chi-square test and Student t-test.  
P value less than 0.05 was considered as statistically significant.  
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5. OBSERVATIONS AND RESULTS 
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OBSERVATIONS AND RESULTS 
 
Table1: Distribution of subjects according to age 
Age 
Group 
Group A 
N (%) 
Group B 
N (%) 
Total 
N (%) 
18-28 20 23 43      (37.07) 
28-38 17 13 30      (25.86) 
38-48 16 14 30      (25.86) 
48-58 05 08 13      (11.21) 
Total 58 58 116    (100) 
Mean age 33.93 ±10.32 34.86±11.43 * P> 0.05 
 
* (p>0.05 not significant) 
 
In the above table it was observed that mean age among Group A and Group B 
were 33.93± 10.32 and 34.86 ± 11.43 years respectively.  
This difference was not statistically significant. (p>0.05) 
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Figure 1: Age wise distribution of subjects
  
Large numbers of subjects observed in younger age group (18-28years) while 
small numbers of participants were present in elder age group. (48-58years)  
Table 2: Demographic data 
 
 
Mean age observed in both groups were 33.93 and 34.86 respectively. Average 
height and weight in Group A and Group B were 152.95, 153.02 cms and 54.93 
and 54.83 kg. 
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Mean age  33.93± 10.31 34.86 ± 11.43  0.46 
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Mean weight  54.93 ± 9.84 54.83 ± 8.72 0.06   
Mean BMI 23.54±2.56 23.25±2.45 0.8 
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Figure 2: Mean Age among the study groups
 
Figure 3: Mean weight and height among the study Groups
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 Table 3: Distribution of subjects according to sex 
Sex Group A  
N (%) 
Group B 
 N (%) 
Total  
N (%) 
Male 27 ( 23.27) 39 (33.62) 66  (56.90) 
    
Female 31 (26.73) 19 (16.38) 50  (43.10) 
    
Total 58 (50) 58 (50) 116    (100) 
 
 
In our study 66 (56.90%) were males and 50 (43.10%) were females. The 
distribution of men and women among both the groups were nearly similar and 
there was no statistically significant difference. 
Figure 4: Distribution of sex (%) among both study groups 
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Table 4: Risk factors among study groups: 
 
 
Risk factor 
 
 
Group A 
 
Group B 
 
P value 
Female Gender 31/58 (53%) 19/58(33%)  0.02 
Non smokers 52/58 (89%) 49/58 (84%) 0.4 
Duration of surgery > 
2 hrs 
7/8(88%) 13/20 (65%)  0.23 
 
In group A, female patients were 20% more as compared to group B. In both 
groups non smokers were having almost equal percentage. In group A, surgical 
time was prolonged for more than 2 hours in 88% of subjects which was higher 
than group B (65%). 
 
Figure 5: Risk factors among group A and group B 
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Table 5: Mean and SD of pulse among the study groups 
 
Pulse rate / min Group Mean SD 
Pre-op 
Group A 78.91 6.809 
 
Group B 81.05 9.212 
Pre-ind 
Group A 83.07 10.244 
 
Group B 85.22 11.278 
Intra-op 
Group A 82.98 8.904 
 
Group B 86 13.54 
Post-op (0) 
Group A 80.95 11.075 
 
Group B 79.48 11.509 
Post-op (6) 
Group A 80.83 9.156 
 
Group B 79.57 9.599 
Post-op (12) 
Group A 80.81 9.802 
 
Group B 80.1 10.767 
Post-op (24) 
Group A 81 10.333 
 
Group B 79.83 9.217 
Post-op (48) 
Group A 79.83 9.552 
 
Group B 79.19 8.642 
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Table 6: Mean and SD of systolic BP among the study groups 
 
Systolic BP 
(mmHg) 
Group  Mean  SD 
Pre-op 
Group A 115.62 9.525 
 
Group B 115.55 10.212 
Pre-ind  
Group A 116.34 7.67 
 
Group B 117.03 12.001 
Intra-op 
Group A 117.31 10.705 
 
Group B 116.45 12.151 
Post-op (0) 
Group A 120.17 13.566 
 
Group B 121.28 13.976 
Post-op (6) 
Group A 118.97 13.103 
 
Group B 117.86 9.099 
Post-op (12) 
Group A 116.9 8.779 
 
Group B 118.24 10.794 
Post-op (24) 
Group A 117.86 9.38 
 
Group B 117.93 8.385 
Post-op (48) 
Group A 118.66 9.473 
 
Group B 118.28 9.525 
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Table 7: Mean and SD of diastolic BP among the study groups 
 
Diastolic BP 
(mmHg) 
Group  Mean  SD 
Pre-op 
Group A 75.86 7.234 
 
Group B 75.52 7.411 
Pre-ind  
Group A 75.41 6.733 
 
Group B 75.69 6.916 
Intra-op 
Group A 75.93 9.485 
 
Group B 76.34 8.062 
Post-op (0) 
Group A 76.31 9.228 
 
Group B 76.17 9.094 
Post-op (6) 
Group A 75.83 8.396 
 
Group B 74.38 7.845 
Post-op (12) 
Group A 76.74 7.01 
 
Group B 75.72 6.429 
Post-op (24) 
Group A 74.59 7.876 
 
Group B 74.24 6.511 
Post-op (48) 
Group A 74.21 7.62 
 
Group B 74.41 5.968 
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Table 8: Mean and SD of RR among the study groups 
 
RR (cycles/min) Group  Mean  SD 
Pre-op 
Group A 18.95 2.502 
 
Group B 18.14 2.893 
Pre-ind  
Group A 18.78 2.492 
 
Group B 17.95 2.658 
Intra-op 
Group A 13.28 1.387 
 
Group B 12.62 0.933 
Post-op (0) 
Group A 19.69 2.624 
 
Group B 19.55 2.226 
Post-op (6) 
Group A 19.28 2.726 
 
Group B 18.62 2.491 
Post-op (12) 
Group A 18.93 2.316 
 
Group B 18.33 2.438 
Post-op (24) 
Group A 18.34 2.213 
 
Group B 18.09 2.187 
Post-op (48) 
Group A 18 2.184 
 
Group B 17.47 1.958 
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Table 9: Mean and SD of temperature among the study groups 
 
Temperature (
0
F) Group  Mean  SD 
Pre-op 
Group A 98.16 0.325 
 
Group B 98.18 0.277 
Pre-ind  
Group A 98.12 0.297 
 
Group B 98.25 0.292 
Intra-op 
Group A 98.12 0.302 
 
Group B 98.2 0.353 
Post-op (0) 
Group A 98.34 0.289 
 
Group B 98.36 0.361 
Post-op (6) 
Group A 98.35 0.516 
 
Group B 96.7 12.122 
Post-op (12) 
Group A 98.24 0.363 
 
Group B 98.19 0.333 
Post-op (24) 
Group A 98.19 0.247 
 
Group B 98.08 0.207 
Post-op (48) 
Group A 98.17 0.271 
 
Group B 98.13 0.246 
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Table 10: Mean and SD of SPO2 among the study groups 
 
SPO2 (%) Group  Mean  SD 
Pre-op 
Group A 98.93 0.413 
 
Group B 98.95 0.223 
Pre-ind  
Group A 99.33 0.758 
 
Group B 99.17 0.679 
Intra-op 
Group A 99.29 0.795 
 
Group B 99.26 0.715 
Post-op (0) 
Group A 98.78 1.325 
 
Group B 98.9 0.968 
Post-op (6) 
Group A 99.03 1.27 
 
Group B 98.9 1.087 
Post-op (12) 
Group A 99.02 1.147 
 
Group B 99.12 0.88 
Post-op (24) 
Group A 98.76 1.418 
 
Group B 99.05 0.847 
Post-op (48) 
Group A 99 1.009 
 
Group B 99.21 0.744 
 
There was no difference in mean vital statistics in both the groups during pre-
operative, pre-induction, intra-operative and post-operative period.  
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Figure 6: Trend of pulse rate (before and after surgery) 
 
Figure 7:  Blood pressure trend (before and after surgery) 
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Figure 8: Pre, intra and post-op RR trend   
 
 
Intra-operative dip  in  RR was due to elective    ventilation  where   RR was    set        
around         12-14/min. 
Figure 9: Pre, intra and post-op temp. trend   
 
 
Figure 10: Pre, intra and post-op SPO2 trend   
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Table 11: Distribution of various surgeries in study groups 
 
Type of surgery  Group A Group B Chi square 
test  
  
P value 
Oro-maxillary  08/58 
(14%) 
07/58 
(12%) 
0.07 0.7 
Laparoscopic 
Abdominal 
14/58 
(25%) 
17/58 
(29%) 
0.39  0.5 
LSCS nil 01/58 (2%)    
Gynaecological 
Surgeries 
04/58 (7%) 04/58 (7%)   
Orthopaedic 
surgeries 
04/58 (7%) 05/58 (9%) 0.12 0.7 
ENT surgeries 10/58 
(17%) 
10/58 
(17%) 
   
Thyroid surgery 02/58 (3%) 04/58 (7%) 0.7 0.4 
Spine Surgery 03/58 (5%) nil    
Dental surgery 02/58 (3%) nil    
General  surgery 
excluding thyroid 
and laparoscopic 
procedures 
03/58 (5%) 05/58 (9%) 0.54 0.4 
Radical Neck 
Dissection 
07/58 
(12%) 
02/58 (3%) 3.01 0.08 
PCNL 01/58 (2%) 03/58 (5%) 1.04 0.3 
Total 58/58 58/58   
 
In both the groups, laparoscopic surgeries were higher in number and ENT 
surgeries were equal in each group. 
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Figure 11: Types of surgeries performed among the study groups 
 
 
 
Abdominal laparoscopic surgeries were the most common type of surgery (25% 
and 29%) in our study.  In both groups, ENT surgeries were equal in number 
(10, 17%).  Oro-maxillary and radical neck dissection surgeries were more in 
group A as compared to group B. Least common surgeries were LSCS (nil) in 
group A and spine and dental surgeries (nil) in group B. 
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Figure 12: comparison of investigations among study groups 
    
 
   
   
   
Mean HB%, TLC values, Blood sugar values and renal parameters did not show 
any significant difference among the groups. 
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Table12: EFFICACY PARAMETERS 
 
Efficacy parameters  
 
Group A (n=58) 
 
Group B (n=58) 
 
P value 
1.Complete response 50 38 0.009
* 
2.Use of rescue medication 8 20 0.009
* 
3.Gratification score   
 
 
 
 
 
 
0.0001
* 
 
 
 
DG 2 9 
NGNDG 8 22 
GR 43 26 
HGR 5 1 
4. Severity of nausea  
0.03
* 
Nil  50 38 
Mild 4 12 
Moderate 4 08 
  
Efficacy of palonosetron was assessed by CR, number of time rescue 
medication used, overall gratification and nausea severity score by VRS showed 
statistically significance. 
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Figure13: Nausea severity assessed by VRS 
 
 
Figure14: Gratification score assessed by 5 point Likert scale 
GS2: disgratified, GS3:neither gratified not dis-gratified, GS4:gratified  
and GS5:highly gratified. 
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Figure 15: Use of rescue medications in group A and B 
 
 
Figure 16: Episodes PONV within first 48 hrs of surgery 
 
In group A, 8 had PONV while in group B, 20 had PONV. 
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Table 13: Incidence of PONV (%) in various surgeries in Palonosetron 
group 
 
Type of surgery Percentage  
ENT surgery 37.50% 
Laparoscopic surgery 25% 
Oro-maxillary Surgery 25% 
Thyroidectomy 12.50% 
 
 
Figure 17: Incidence of PONV in different types of surgeries in 
palonosetron group 
 
 
 
 
 
 
 
Maximum episodes of PONV has been observed in ENT surgeries in group A. 
Laparoscopic and Oro-maxillary surgeries were having equal number of PONV 
episodes. 
Minimal incidence of PONV was seen in thyroid surgeries. 
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Table 14: Incidence of PONV (%) in various surgeries in ondansetron 
group 
 
 
Type of surgery                                          Percentage  
ENT 15% 
Thyroidectomy  20% 
Orthopaedic surgery 10% 
Laparoscopic surgery 30% 
Gynaecologic surgery 10% 
Oro-maxillary-surgery 10% 
PCNL 5% 
 
 
Figure 18: PONV percentage in various surgeries  in ondansetron group 
 
 
 
 
Maximum incidence of PONV in group B was seen in laparoscopic surgeries 
followed by thyroid surgeries. Incidence of PONV in ENT surgeries in group B 
was 15%. Least incidence was seen in percutaneous nephrolithotomy (PCNL). 
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Table 15: Distribution of gender in PONV patients: 
 
Gender Group A (%) Group B (%) 
Male  25 % 50 % 
Female 75 % 50 % 
 
 
 
Figure 19: PONV incidence among males and females in study groups 
 
 
 
 
 
 
 
 
In group A, incidence of PONV was higher in females as compared to males 
(3:1) but was equal (1:1) in group B. 
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Table16: Incidence of PONV in acute phase and late phase 
 
Group PONV  
0-6 hrs 
PONV 
6-12 hrs 
PONV 
12-24 hrs 
PONV 
24-48 hrs 
Total 
Group A 0 0 2/8 (25%) 6/8(75%) 8/8 
Group B 0 12 (60%) 7 (35%) 1 (5%) 20/20 
 
In early phase (0-24hrs) PONV incidence in group A was less (25%)  as 
compared to group B(95%) but in late phase PONV incidence was high. 
 
Figure 20: Mean age and BMI in PONV patients in study groups 
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Table 17: Safety parameters 
Adverse effects Group A Group B 
Headache 2 4 
Constipation 1 1 
Dizziness 1 2 
Fatigue  1 1 
Itching 0 0 
Insomnia 1 1 
QTC  prolongation 0 1 
   
 
Figure 21: Adverse effects among the study groups: 
 
 
Both the groups did not show any serious adverse event. Most common side 
effect was headache in both groups and least common side effect was rash or 
itching. QTc prolongation was seen in ondansetron group in single patient while 
none in palonosetron receivers. 
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6. DISCUSSION: 
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DISCUSSION 
This study was undertaken to assess safety and efficacy of palonosetron versus 
ondansetron. Two groups with equal number of participants were chosen and 
total 116 participants were recruited in the study. 
Mean age among group A and group B were 33.93and 34.86years respectively 
and does not show any statistical significance. In younger age group (18-28) 
maximum numbers of subjects were observed and in elder age group (48-58) 
minimum numbers of subjects were observed. Among 116 participants 
recruited, 56.9 % were male and 43.1 % were female. Sex distributions among 
both the groups were same with no statistical difference.  
Mean body weight, height and BMI in group A were 54.93 kg, 152.95 cm and 
23.54 kg/m
2
 respectively. In another group B, mean weight, height and BMI 
were 54.83 kg, 153.02 cm and 23.25 kg/m
2
. There were no statistically 
significant differences among the groups in relation to demographic parameters. 
Vital parameters like pulse, systolic and diastolic BP, RR, temperature and 
SPO2 were assessed pre-operatively, before induction, during surgery and post-
operatively after 6,12,24 and 48 hours. It was observed that there were no 
significant differences in mean vital parameters. 
Mean pulse rate was slightly high during pre-operative and induction period 
which may be due to initial anxiety of the patient just before undergoing 
surgery. Rise in mean systolic BP during intra-operative session was due to  
77 | P a g e  
 
increased sympathetic activity and during post-operative period was due to pain.  
Small dip in mean RR was because of artificial ventilation provided during 
general anaesthesia at the rate of 12-14 breaths/min. 
The most commonly performed surgeries in both the groups were laparoscopic 
abdominal surgery followed by ENT and Oro-maxillary surgeries. In ENT 
category, common surgeries were septo-plasty and tonsillectomy while in Oro-
maxillary category common surgeries were ORIF (open reduction and internal 
fixation) mandible and radical neck dissection. There was no statistical 
significance between group A and group B in relation to types of surgery. 
Efficacy parameters were assessed by complete response, number of rescue 
anti-emetics used, nausea severity and overall satisfaction score. 
Complete response was evaluated as no nausea, vomiting and no need of rescue 
anti-emetics. Out of 116 patients, 88 were complete responders among which 50 
(86%) were from palonosetron group and 38(65%) were from ondansetron 
group. The difference of numerical value of 12 among the groups was highly 
significant. Similar results were seen in a study published by Musso
99
 and 
colleagues which was prospective study conducted on different types of cancer 
patients. It showed 80% CR for CINV in palonosetron group and 60% in 
ondansetron group. Mattiuzzi et al
89
 also demonstrated higher CR in 
palonosetron arm versus ondansetron arm. The study conducted by 
Chattopadhyay
94
 and associates where PONV was assessed in post caesarean 
delivery. In the same study, CR was observed in 85% of subjects using  
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palonosetron and 83% of subjects using ramosetron. In another study for 
prevention of CINV, Schwartzberg and colleagues
100
 stated overall CR 51% in 
palonosetron group and 40% in ondansetron, dolasetron or granisetron group. 
Our study demonstrated higher CR rates compared to previous study. This may 
be due to recruitment of subjects with less number of high risk population in our 
study. 
In our study, number of times rescue medications used in palonosetron group 
and ondansetron group were 8 and 20 respectively. In ondansetron group, more 
number of patients required rescue anti-emetics as compared to palonosetron 
group and the difference was statistically significant. Sharma and colleagues
85
 
study also showed higher (20%) use of rescue medication in ondansetron group 
as compared to palonosetron group (4%). Kim and associates
87
 found less use of 
rescue anti-emetics in palonosetron group than ondansetron or ramosetron 
group. 
Out of 116 patients, only 28 had nausea among which 8 belonged to 
palonosetron group and 20 belonged to ondansetron group. Of 8 patients from 
palonosetron receivers, 4 had mild nausea and remainder had moderate nausea 
while in ondansetron group, 12 had mild nausea and rest had moderate nausea. 
None had severe nausea in both the groups. Severity of nausea among the group 
was statistically significant. Similar results were observed by Bajwa
80
 et al study 
where 6.66% had nausea and 3.33% had vomiting in palonosetron group while 
20% observed nausea and 13.33% observed vomiting in ondansetron group and 
the difference was statistically significant.  
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Schwartzberg
100 
and associates demonstrated no significant difference between 
palonosetron and other 5HT3 antagonists during early post-chemotherapy period 
but significant difference was observed in delayed chemotherapy period. 
PONV episodes during first 48 hrs were 8 (13.76%) in palonosetron group and 
20 (34.4%) in ondansetron group which was highly significant. Consistent 
results were also observed in previous study conducted by Kim
93
 and associates 
where PONV incidence in palonosetron group was 22.2% and 77% in 
ondansetron group. Lower values observed in our study were due to patient 
related and surgery related factors. Higher incidence was because of recruitment 
of more high risk predictors of PONV in other study.  
Overall satisfaction score was assessed by 5 point Likert score. In palonosetron 
group, gratified participants were 43, highly gratified were 5, 8 were of neutral 
opinion and 2 were disgratified. In ondansetron group, 26 were gratified, 22 
were neutral, one was highly gratified and 9 were disgratified.  Overall 
gratification score (82% vs 46%) with anti-emetic drugs showed significant 
difference between the groups. An analogous  results were observed by 
Mansour
86
 study. In a three different groups receiving palonosetron or saline or 
metoclopramide along with dexamethasone had total satisfaction score 88%, 
48% and 62% respectively.  
In our study, patients from palonosetron group had higher CR, lesser nausea, 
lesser vomiting and higher satisfaction score as compared to ondansetron  
group. Even though both drugs belong to same structural group, palonosetron 
was much superior in controlling PONV. Few studies conducted
73, 78, 82, 85, 88, 89, 
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98 
among two groups have showed domination of palonosetron as anti-emetic 
agent. Palonosetron has ranked one
93
 in anti-emetic property than other 5HT3 
antagonists like ramosetron and granisetron. Even with combination 
chemotherapy
85
 palonosetron appears to be effective in controlling PONV. 
In spite higher number of females in our study group, PONV incidence was 
(14%) as compared to ondansetron group (34.48%). Palonosetron proved its 
utility not only in normal patients but also in high risk individuals
73,75,79,81
 in 
controlling episodes of PONV. Superior efficacy of palonosetron could be due 
to its higher receptor affinity
74,75
 due to allosteric site
74
 and longer half life
12,73
. 
Palonosetron was not only effective in reducing overall incidence of PONV but 
in controlling PONV episodes during early post-operative period (0-24hrs). This 
cardinal finding has more value when previous study
101
 has been demonstrated 
efficacy of other 5HT3 antagonist to palonosetron in decreasing early episodes 
of PONV. From above mentioned findings we can conclude that palonosetron is 
also equally competent to other 5 HT3 antagonist in controlling early phase 
PONV.  
Pre-operative, intra-operative and post-operative vital parameters were 
compared in both the groups showed not much significance among the groups. 
Fewer exceptions were pre-induction temperature, intra-operative RR and post-
operative temperature where p value was statistically significant. As 
temperature and RR can be affected by various external factors like infection, 
underlying pathology, effect of anaesthetic agents, this statistical difference 
among two groups do not carries any significance. 
81 | P a g e  
 
Various clinical trials had been supporting about safety
96, 102 
of palonosetron. In 
our study palonosetron was well tolerated and was equally safe as ondansetron 
because both group had mild and lesser side effects. Side effects in both the 
groups were similar to previous studies. The common side effects observed 
were headache, constipation, fatigue and insomnia. Most common side effect in 
both group was headache. Mattiuzzi
 
et al
89 
demonstrated most frequent adverse 
effect as headache and constipation. A study carried out by Sadaba et al
83
 also 
stated headache, constipation and diarrhoea as frequent adverse events. No one 
from either group developed rash or itching or diarrhoea. A single participant 
had QT prolongation in ondansetron group but no one had it from palonosetron 
group. Very few studies
96
 have demonstrated cardiac safety of palonosetron 
with increasing dose. In our study, no effect was observed on electrocardiogram 
measured by QT prolongation. Mean QTc for palonosetron group before and 
after surgery was 0.391 and 0.396 ms while mean QTc for ondansetron group 
before and after surgery was 0.393 and 0.396 ms respectively. Very few 
studies
97, 103 
have showed risk of QT prolongation and development of 
ventricular tachycardia while using ondansetron. As in ondansetron group, only 
one patient had QT prolongation and not much difference in mean QTc among 
both the groups, cardiac repolarisation measured by QTc interval cannot be 
generalised to all ondansetron population. Superiority of palonosetron in 
relation to cardiac safety cannot be concluded  
with above inadequate data. To prove cardiac safety of palonosetron over 
ondansetron more number of subjects will be required. Hence we can draw 
inference that palonosetron is not superior to ondansetron in terms of safety but 
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equally safe as far as side effects are concerned. There is definite scope to 
explore cardiac safety profile of palonosetron over ondansetron in large sample 
size population to affirm higher safety of palonosetron.  
In our study, there was no loss of follow-up as patients were monitored from 0-
48 hrs after surgery with regular intervals. Also no deaths were observed in 
either group. 
Our study has few limitations… 
First, non-inclusion of placebo group to evaluate baseline incidence but 
withholding antiemetic therapy in post-operative patients would be like denying 
treatment to them.  
Second, propofol containing regimen used for induction of anaesthesia may 
interfere with incidence of PONV.  
Third, Patient satisfaction score cannot be considered as end point because 
subjective feeling may show wide variation in groups. 
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7. SUMMARY 
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SUMMARY 
The present double blinded, randomized controlled study was carried out to 
evaluate efficacy and safety of palonosetron against ondansetron in post-
operative patients undergoing General Anaesthesia. 
A total 116 patients were recruited in the study after fulfilling inclusion and 
exclusion criteria. After block randomization subjects were allocated in two 
different groups. Group A was given IV palonosetron 75 µg and group B was 
given IV ondansetron 8 mg before induction of anaesthesia. All patients were 
followed up intra-operatively and post-operatively. 
The study revealed the following findings: 
The mean age among group A and group B patients were 33.93± 10.32 and 
34.86 ± 11.43 years respectively. 
The numbers of subjects in age groups 18-28 years were more in both groups 
(20 and 23 respectively) 
Among 116 participants 66 were male and 50 were female. 
The mean weight, height and BMI in group A and group B were 54.93±9.84 kg, 
152.95±6.81 cm 23.54± 2.56 kg/m
2
 and 54.83±8.72 kg, 153.02±6.38 cm, 23.25± 
2.45 kg/m
2
respectively. 
Vital parameters recorded before induction, during and after surgery showed no 
statistical significance with few exceptions. 
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Efficacy parameters were evaluated by CR, nausea severity, use of rescue 
medication and overall satisfaction score. For all efficacy parameters statistical 
values were highly significant.  
Safety parameters were assessed by comparing episodes of adverse drug events 
and cardiac safety was evaluated by measuring QTc interval from post-operative 
ECGs. There was no significant difference in adverse events among the groups. 
Although QTc prolongation in one subject was seen in ondansetron group was 
not considered significant due to small sample size. 
From statistical data analysis, the present study inferred that second generation 
palonosetron is more effective and equally safe to ondansetron in preventing 
PONV in post-surgical patients undergoing general anaesthesia. 
As our study could not able to prove better safety of palonosetron due to less 
number of adverse effects, further research is suggested to assess safety of 
palonosetron with  larger sample size population. 
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8. CONCLUSION 
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CONCLUSION 
 
Thus from the current study we conclude that…  
1. Palonosetron was more efficacious than ondansetron in controlling 
PONV in a post-surgical patients undergoing general anaesthesia.  
 
2. In addition, palonosetron was also effective in reducing PONV in first 24 
hours of post-operative period. Overall satisfaction was high in 
palonosetron receivers than patients whom ondansetron was given. 
 
3. Palonosetron was found equally safe as Ondansetron. 
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List of abbreviations 
(Annexure I) 
 
1. PONV:  Post operative nausea vomiting 
2. CINV: chemotherapy induced nausea vomiting 
3. ECG: Electrocardiogram 
4. CR complete response 
5. CC: complete control 
6. MD-CT : Multi day based chemotherapy 
7. I.V:  Intravenous 
8. CI: Confidence interval 
9. PCA: Patient controlled analgesia 
10.  Sc  : Subcutaneous 
11.  Ms : Millisecond 
12.  PR: Pulse rate 
13.  RR: Respiratory rate 
14.  BP: Blood pressure 
15.  SPO2 : Oxygen saturation  
16.  Pre-op:  Pre-operative 
17.  Pre-ind:   Pre-induction 
18.  Intra-op: Intra-operative 
19.  Post-op : Post- operative 
20.  AUC: Area under curve 
21.  ASA : American Society of Anaesthesiologists 
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22.  AML : Acute Myeloid Leukaemia  
23.  OPD : Out Patient Department  
24.  QTc : Corrected QT interval 
25.  TLC : Total leukocyte count 
26.  BUL : Blood urea level 
27.  F BSL :  Fasting Blood sugar level 
28.  PP BSL: Post prandial Blood sugar level 
29.  cms : centimetres  
30.  SD : Standard deviation 
31.  GS : Gratification score 
32.  ORIF : Open reduction and internal fixation 
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Informed consent document 
Subject Information sheet  
 (Annexure II A) 
You are invited to participate in this study titled “to study efficacy and safety of 
intravenous palonosetron against ondansetron in post surgical patients 
undergoing general anaesthesia.” 
 
Study Purpose: 
The purpose of this study is to find out whether there is difference in safety and 
efficacy of Intravenous palonosetron versus intravenous ondansetron in patients 
undergoing surgery under general anaesthesia. 
 
Study Details: 
 Along with you total 100 patients will be included in this study. 
 You will be enrolled only after giving your voluntary consent. 
 This study involves administration of either injection palonosetron or 
ondansetron before anaesthesia as well as collection of 5 ml of blood 
from vein by expert for routine baseline investigations like complete 
blood count, Fasting and post prandial BSL, Blood urea, serum 
creatinine, X-ray Chest and ECG. 
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 After 4 hrs of surgery ECG will be taken once again. You will be asked 
questions from the formatted questionnaire and you will be requested to 
answer this in the format mentioned in proforma. 
 
Benefit of participating in the study: By participation in this study you will be 
prevented from most troublesome symptom like Post operative nausea vomiting 
(PONV). 
 
Risks involved in participation of this study: As these antiemetic agents have 
adverse effect on heart, administration of this drug may lead to fast and irregular 
rhythm of heart. If any unwanted side effects occur, it will be treated free of cost 
and your health will be safe guarded. 
 
Rights: participation in this study is purely voluntary. If you do not want to 
participate you can withdraw from study at any time. 
 
Confidentiality: your participation will be kept confidential. The investigators 
and other authorized personnel will only have access to the data. The 
information will be used for publication and further research without revealing 
your identity. 
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Subject consent form 
(Annexure II B) 
I, the undersigned confirmed that.. 
 I have read and understood the information about the study titled “to 
study efficacy and safety of intravenous palonosetron against 
ondansetron in post surgical patients undergoing general anaesthesia” as 
provided in information sheet. 
 I have been given opportunity to ask questions about the project and my 
participation. 
 I understand that I can withdraw myself from study at any time without 
giving any reason. 
 Procedures regarding confidentiality have been very well explained to 
me. 
 The use of data for publication, research sharing and archiving has been 
explained to me. 
 I voluntarily agree to participate in the study research. 
 I along with the researcher agree to sign and date this informed consent 
form. 
 Signature                                                               Signature 
Name of the participant:                                       Name of the Researcher: 
Date: Date: 
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Investigator’s Declaration 
(Annexure II C) 
I have accurately read the information sheet for the study titled “to study 
efficacy and safety of intravenous palonosetron against ondansetron in post 
surgical patients undergoing general anaesthesia” to the potential participant and 
to the best of my knowledge participant understands that following will be done.  
1. Injection of palonosetron or ondansetron will be given prior to anaesthesia. 
2. About 5 ml blood will be aspirated for routine investigations mentioned in 
information sheet. 
3. Chest X ray will be taken before surgery. 
4. ECG will be taken before surgery and after 4 hrs of surgery. 
5. In case of unexpected events, reactions treatment will be given free of cost. 
I confirm that participant was given as opportunity to ask questions related to 
study and all questions asked have been answered correctly to the best of my 
knowledge. I confirmed that individual has not been pressurised to give consent 
rather consent is obtained freely and voluntarily.  A copy of this ICF has been 
provided to the participant. 
 
Date:                                   Signature of the researcher taking consent 
 
                                    (Name of the researcher taking consent:                 ) 
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Ethical clearance document 
(Annexure III) 
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Plagiarism certificate 
(Annexure IV) 
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PROFORMA 
(Annexure V) 
 
Name: 
Age:                                                                              Sex: 
Address:                                           Operation performed: 
H/O Medical illness:  Like DM, HT, Asthma, Heart disease, IHD 
LMP: 
H/o Alcoholism, h/o ongoing steroids, h/o ongoing anti-emetics, h/o nausea 
vomiting, h/o APD 
Before entering OT: 
P:                   BP:                    RR:                              Temp:         SPO2: 
Systemic Examination:  
CVS:                    
 RS:           
CNS:                 
 PA: 
Before Induction In OT: 
Vitals: P:                   BP:                    RR:                              Temp: 
SPO2:                       ECG Monitor: 
 
Intra-operative parameters: 
Vitals: P:                   BP:                    RR:                              Temp: 
SPO2:                       ECG Monitor:                 Any adverse event if any: 
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Post- operative Parameters: 
Parameters  Pulse  BP RR Temp. SPO2 
0 hrs      
6 hrs      
12 hrs      
24 hrs      
48 hrs      
 
  ECG at 4 hrs 
Questionnaire    (To be asked post operatively)  
1)  Have you vomited?           Yes / No 
2) Do you have nausea?          Yes/No 
3)  How severe is nausea?   (Mild/ Moderate/ Severe by VRS)      
4) Do you have rash/itching? 
5) Does patient receive rescue anti-emetic? if yes how many times? 
6) Patient gratification score with 5 point Likert scale (strongly disgratified, 
disgratified, neither gratified nor disgratified, gratified, strongly gratified) 
7) Does patient has any other adverse event? 
8) Time of first episode after how many hours of surgery? 
Investigations : 
CBC: 
Chest X-Ray (PA): 
ECG: 
Renal Parameters:   BUL and Serum Creatinine 
Diabetic Profile:  BSL: (F)            (PP) 
Urine (R) 
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Data 
(Annexure VI) 
Group A 
Sr No IP Age Sex Ht(cms)  Wt(Kg)  BMI 
   
QTc ECG - 
              pre-op  4 hrs 
1 1408140010 23 M 160 62 24.2 0.4 0.42 
2 1408140014 35 F 158 55 22 0.4 0.42 
3 809140015 40 F 149 52 23.4 0.4 0.43 
4 809140043 35 F 152 56 24.2 0.42 0.44 
5 2509140003 25 M 150 56 24.9 0.4 0.41 
6 2509140009 22 F 156 50 20.5 0.4 0.4 
7 2510140011 40 F 155 55 22.9 0.4 0.42 
8 2510140012 45 F 150 44 19.6 0.4 0.41 
9 1211140002 30 F 154 42 17.7 0.38 0.38 
10 1211140006 58 F 151 49 21.5 0.4 0.41 
11 302150045 37 F 155 56 23.3 0.4 0.4 
12 902150012 46 F 147 49 22.7 0.4 0.41 
13 1102150050 20 F 140 35 17.9 0.41 0.42 
14 1602150017 35 F 152 59 25.5 0.39 0.39 
15 1802150056 24 M 148 43 19.6 0.39 0.4 
16 2802150008 20 F 152 59 25.5 0.38 0.38 
17 903150011 21 M 144 44 21.2 0.39 0.39 
18 903150014 21 M 160 60 23.4 0.39 0.39 
19 903150017 29 F 145 48 22.8 0.38 0.4 
20 903150021 36 M 159 69 27.3 0.38 0.4 
21 1003150043 29 M 158 67 26.8 0.38 0.39 
22 1003150045 34 F 137 71 37.8 0.4 0.4 
23 1504150014 49 F 154 60 25.3 0.4 0.41 
24 1504150015 38 F 156 60 24.7 0.38 0.39 
25 2004150198 21 M 168 72 25.5 0.38 0.39 
26 2304150016 40 F 150 59 26.2 0.39 0.4 
27 2704150006 24 M 155 49 20.4 0.39 0.4 
28 2704150024 24 F 140 39 19.9 0.39 0.41 
29 305150010 39 M 159 62 24.5 0.39 0.39 
30 505150049 52 F 139 62 32.1 0.38 0.38 
31 605150001 27 M 149 49 22.1 0.4 0.4 
32 605150054 20 F 153 55 23.5 0.4 0.41 
33 2905150046 35 M 163 68 25.6 0.39 0.4 
34 106150047 38 F 145 39 18.5 0.39 0.39 
35 306150013 39 F 140 39 19.9 0.38 0.39 
36 806150099 21 M 151 47 20.6 0.39 0.38 
37 1006150005 40 M 158 66 26.4 0.38 0.4 
38 1106150054 30 M 160 67 26.2 0.4 0.4 
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Sr No IP Age Sex Ht(cms)  Wt(Kg)  BMI 
   
QTc ECG - 
39 1506150001 20 M 157 56 22.7 0.4 0.4 
40 2406150038 25 F 149 42 18.9 0.4 0.38 
41 2506150021 38 F 148 54 24.7 0.39 0.4 
42 607150040 46 F 156 52 21.4 0.39 0.42 
43 907150048 45 F 150 52 23.1 0.39 0.4 
44 1507150037 40 F 148 42 19.2 0.38 0.4 
45 1507150039 23 M 159 49 19.4 0.39 0.39 
46 1507150040 32 M 156 71 29.2 0.4 0.4 
47 2807150047 21 M 159 63 24.9 0.4 0.39 
48 208150014 39 M 148 44 20.1 0.38 0.38 
49 508150027 39 M 168 72 25.5 0.38 0.4 
50 508150042 33 F 158 57 22.8 0.39 0.39 
51 1808150030 25 M 162 70 26.7 0.36 0.36 
52 1509150061 45 F 153 47 20.1 0.38 0.4 
53 1410150063 23 M 156 61 25.1 0.38 0.41 
54 211150050 40 M 147 48 22.2 0.39 0.39 
55 411150030 26 M 160 68 26.6 0.4 0.4 
56 1412150012 47 M 159 63 24.9 0.4 0.38 
57 1801160029 55 F 149 42 27.9 0.38 0.38 
58 2401160009 30 M 157 59 23.9 0.39 0.39 
Sr No Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
                  
1 0 0 0 0 0 4 0   
2 0 0 0 0 0 3 0   
3 0 0 0 0 0 4 0   
4 0 0 0 0 0 4 0   
5 0 0 0 0 0 4 0   
6 0 0 0 0 0 3 0   
7 0 0 0 0 0 4 0   
8 0 0 0 0 0 4 0   
9 0 0 0 0 0 4 0   
10 0 0 0 0 0 4 0   
11 0 0 0 0 0 4 0   
12 0 0 0 0 0 4 0   
13 1 1 2 0 2 2 0 24 hrs 
14 0 0 0 0 0 4 0   
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Sr No Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
15 0 0 0 0 0 4 0   
16 0 0 0 0 0 4 0 
 17 1 1 2 0 1 2 0 24 hrs 
18 0 0 0 0 0 4 0   
19 0 0 0 0 0 5 0   
20 0 0 0 0 0 4 0   
21 0 0 0 0 0 5 0   
22 0 0 0 0 0 5 0   
23 0 0 0 0 0 4 0   
24 0 0 0 0 0 4 0   
25 0 0 0 0 0 4 0   
26 0 0 0 0 0 4 0   
27 0 0 0 0 0 4 0   
28 0 0 0 0 0 4 0   
29 1 1 2 0 1 3 0 24 hrs 
30 0 0 0 0 0 4 0   
31 0 0 0 0 0 4 0   
32 0 0 0 0 0 4 0   
33 0 0 0 0 0 4 0   
34 0 0 0 0 0 4 0   
35 0 0 0 0 0 5 0   
36 0 0 0 0 0 4 0   
37 0 0 0 0 0 4 0   
38 0 0 0 0 0 4 0   
39 0 0 0 0 0 4 0   
40 0 0 0 0 0 5 0   
41 0 0 0 0 0 4 0   
42 1 1 2 0 1 3 0 12 hrs 
43 1 1 1 0 1 3 0 24 hrs 
44 0 1 1 0 1 3 0 24 hrs 
45 0 0 0 0 0 3 0   
46 0 0 0 0 0 4 0   
47 0 0 0 0 0 4 0   
48 0 0 0 0 0 4 0   
49 1 1 1 0 1 3 0 12 hrs 
50 0 1 1 0 1 3 0 24 hrs 
51 0 0 0 0 0 4 0   
52 0 0 0 0 0 4 0   
53 0 0 0 0 0 4 0   
54 0 0 0 0 0 4 0   
55 0 0 0 0 0 4 0   
56 0 0 0 0 0 4 0   
57 0 0 0 0 0 4 0   
58 0 0 0 0 0 4 0   
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Group B 
Sr.No. IP Age Sex Ht (cms) Wt.(Kg) BMI 
    
QTc ECG - 
              Pre-op  4 hrs 
1 309140012 24 M 150 54 24 0.39 0.39 
2 809140012 40 F 139 44 22.8 0.4 0.4 
3 909140001 42 F 152 58 25.1 0.4 0.4 
4 1909140002 32 M 140 44 22.4 0.39 0.39 
5 2509140007 48 F 148 65 29.7 0.38 0.4 
6 1410140019 22 M 140 63 32.1 0.38 0.4 
7 2310140010 40 F 152 50 21.6 0.39 0.4 
8 2310140012 47 F 152 60 26 0.4 0.39 
9 1012140004 43 M 155 52 21.6 0.4 0.4 
10 1012140008 30 M 155 55 22.9 0.4 0.39 
11 1102150005 26 M 156 64 26.3 0.38 0.4 
12 1102150045 20 M 152 64 27.7 0.39 0.4 
13 1602150002 46 M 156 55 22.6 0.38 0.39 
14 1802150016 45 M 140 40 20.4 0.39 0.4 
15 2502150051 58 F 150 50 22.2 0.4 0.4 
16 2802150004 48 M 155 69 24.6 0.4 0.39 
17 103150008 24 M 155 52 21.6 0.4 0.4 
18 703150012 28 F 146 40 18.8 0.38 0.39 
19 903150022 28 M 156 62 25.5 0.38 0.4 
20 903150033 25 M 163 61 23 0.39 0.4 
21 1703150006 34 M 152 55 23.8 0.39 0.39 
22 2503150080 30 M 152 42 18.2 0.41 0.39 
23 1504150001 34 M 160 65 25.4 0.4 0.4 
24 1504150018 55 F 147 49 22.7 0.4 0.4 
25 1504150019 21 M 153 58 24.8 0.39 0.4 
26 2304150002 26 M 146 43 20.2 0.39 0.4 
27 2604150010 50 F 152 48 20.8 0.4 0.4 
28 2704150021 36 M 156 55 22.6 0.4 0.38 
29 2804150003 24 M 155 66 27.5 0.39 0.39 
30 605150064 23 F 142 41 20.3 0.4 0.4 
31 705150003 27 M 156 57 23.4 0.4 0.4 
32 705150063 47 M 155 63 26.2 0.39 0.39 
33 2305150008 24 M 150 52 23.1 0.39 0.4 
34 2905150039 25 M 160 70 27.3 0.4 0.4 
35 106150048 47 M 166 67 24.3 0.4 0.4 
36 106150049 58 M 159 60 23.7 0.4 0.4 
37 806150067 30 F 147 48 22.2 0.4 0.4 
38 1006150013 43 F 149 45 20.3 0.39 0.4 
39 1006150037 21 M 159 58 22.9 0.39 0.4 
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40 1806150055 34 M 162 60 22.9 0.39 0.39 
41 2506150046 28 F 156 50 20.5 0.39 0.4 
42 2506150052 30 M 156 48 19.7 0.4 0.4 
43 707150044 35 M 155 59 24.6 0.4 0.4 
44 1307150001 50 M 155 59 24.6 0.4 0.4 
45 2007150030 24 F 148 52 23.7 0.39 0.4 
46 2807150039 30 M 160 69 27 0.39 0.39 
47 2907150031 29 F 152 44 19 0.39 0.4 
48 508150024 39 M 152 48 20.8 0.39 0.4 
49 1208150049 49 F 159 54 21.4 0.4 0.39 
50 1308150065 21 M 148 49 22.4 0.4 0.4 
51 1409150029 23 F 144 49 23.6 0.4 0.4 
52 2309150066 58 F 149 42 18.9 0.39 0.39 
53 2909150063 26 M 159 60 23.7 0.39 0.4 
54 3010150034 24 F 148 42 19.2 0.39 0.4 
55 812150015 44 M 165 70 25.7 0.38 0.39 
56 912150047 56 M 158 66 26.4 0.39 0.4 
57 2301160046 20 M 166 67 24.3 0.4 0.4 
58 2801160048 31 F 155 48 20 0.4 0.39 
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Sr No. Q 1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
                  
1 0 0 0 0 0 4 0   
2 0 0 0 0 0 4 0   
3 1 1 2 0 2 2 0 6 hrs 
4 0 0 0 0 0 3 0   
5 0 0 0 0 0 4 0   
6 0 0 0 0 0 4 0   
7 0 0 0 0 0 4 0   
8 0 0 0 0 0 4 0   
9 0 0 0 0 0 4 0   
10 0 0 0 0 0 4 0   
11 0 0 0 0 0 4 0   
12 1 1 2 0 1 3 0 6 hrs 
13 1 1 1 0 1 2 0 6 hrs 
14 0 0 0 0 0 4 0   
15 1 1 2 0 1 2 0 12 hrs 
16 0 0 0 0 0 4 0   
17 0 0 0 0 0 4 0   
18 0 0 0 0 0 4 0   
19 0 0 0 0 0 3 0   
20 0 0 0 0 0 3 0   
21 0 0 0 0 0 3 0   
22 0 0 0 0 0 3 0   
23 1 1 1 0 1 2 0 6 hrs 
24 0 0 0 0 0 3 0   
25 1 1 2 0 2 2 0 12 hrs 
26 0 0 0 0 0 3 0   
27 0 0 0 0 0 3 0   
28 0 0 0 0 0 3 0   
29 0 0 0 0 0 3 0   
30 0 0 0 0 0 4 0   
31 1 1 2 0 1 2 0 6 hrs 
32 0 0 0 0 0 3 0   
33 1 1 1 0 1 3 0 6 hrs 
34 0 0 0 0 0 3 0   
35 0 0 0 0 0 3 0   
36 0 0 0 0 0 4 0   
37 1 1 1 0 1 2 0 12 hrs 
38 0 0 0 0 0 4 0   
39 0 0 0 0 0 4 0   
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Sr No. Q 1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
40 0 0 0 0 0 4 0   
41 1 1 1 0 1 2 0 6 hrs 
42 1 1 1 0 1 3 0 12hrs 
43 1 1 1 0 1 2 0 6 hrs 
44 0 0 0 0 0 4 0   
45 0 0 0 0 0 4 0   
46 0 0 0 0 0 4 0   
47 0 1 1 0 1 4 0 12 hrs 
48 0 0 0 0 0 4 0   
49 1 1 1 0 1 3 0 6 hrs 
50 0 0 0 0 0 4 0   
51 1 1 1 0 2 3 0 6 hrs 
52 0 1 2 0 1 3 0 24 hrs 
53 1 1 2 0 1 3 0 12 hrs 
54 1 1 2 0 2 3 0 6 hrs 
55 0 0 0 0 0 4 0   
56 0 0 0 0 0 4 0   
57 1 1 1 0 1 3 0 6 hrs  
58 1 1 1 0 1 3 0 12 hrs 
